Effects of lithium treatment on oxidative stress markers in mitochondrial complex I and complex III inhibition and after CO2 exposure in SH-SY5Y cells

Author(s):  
Frederic Marmol
2016 ◽  
Vol 96 ◽  
pp. 190-198 ◽  
Author(s):  
Lise Mathieu ◽  
Alexandra Lopes Costa ◽  
Carole Le Bachelier ◽  
Abdelhamid Slama ◽  
Anne-Sophie Lebre ◽  
...  

2019 ◽  
Vol 44 (5) ◽  
pp. 1002-1013 ◽  
Author(s):  
Wen Zhang ◽  
Yunwen Yang ◽  
Huiping Gao ◽  
Yue Zhang ◽  
Zhanjun Jia ◽  
...  

Background: Some researches revealed that mitochondrial dysfunction is associated with various kidney injury. However, the role of mitochondrial dysfunction in the pathogenesis of acute kidney injury (AKI) still needs evidence. Methods: We evaluated the effect of mitochondrial complex I inhibitor rotenone on folic acid (FA)-induced AKI in mice. Results: Strikingly, the mice pretreated with rotenone at a dose of 200 ppm in food showed exacerbated kidney injury as shown by higher levels of blood urea nitrogen and creatinine compared with FA alone group. Meanwhile, both renal tubular injury score and the expression of renal tubular injury marker neutrophil gelatinase-associated lipocalin were further elevated in rotenone-pretreated mice, suggesting the deteriorated renal tubular injury. Moreover, the decrements of mitochondrial DNA copy number and the expressions of mitochondrial Cytochrome c oxidase subunit 1, mitochondrial NADH dehydrogenase subunit 1, and mitochondria-specific superoxide dismutase (SOD2) in the kidneys of FA-treated mice were further reduced in rotenone-pretreated mice, indicating the aggravated mitochondrial damage. In parallel with the SOD2 reduction, the oxidative stress markers of malondialdehyde and HO-1 displayed greater increment in AKI mice with rotenone pretreatment in line with the deteriorated apoptotic response and inflammation. Conclusion: Our results suggested that the inhibition of mitochondrial complex I activity aggravated renal tubular injury, mitochondrial damage, oxidative stress, cell apoptosis, and inflammation in FA-induced AKI.


2011 ◽  
Vol 106 (2) ◽  
pp. 287-297 ◽  
Author(s):  
Mahmood S. Mozaffari ◽  
Babak Baban ◽  
Jun Yao Liu ◽  
Worku Abebe ◽  
Jennifer C. Sullivan ◽  
...  

Author(s):  
Géraldine Leman ◽  
Naïg Gueguen ◽  
Valérie Desquiret-Dumas ◽  
Mariame Selma Kane ◽  
Céline Wettervald ◽  
...  

2016 ◽  
Vol 41 (8) ◽  
pp. 2160-2172 ◽  
Author(s):  
Zuzana Tatarkova ◽  
Maria Kovalska ◽  
Veronika Timkova ◽  
Peter Racay ◽  
Jan Lehotsky ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0144290 ◽  
Author(s):  
Naïg Gueguen ◽  
Valérie Desquiret-Dumas ◽  
Géraldine Leman ◽  
Stéphanie Chupin ◽  
Stéphanie Baron ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Alicia Jiménez-Delgado ◽  
Genaro Gabriel Ortiz ◽  
Daniela L. Delgado-Lara ◽  
Hector Alberto González-Usigli ◽  
Luis Javier González-Ortiz ◽  
...  

Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.


Sign in / Sign up

Export Citation Format

Share Document